Connor Clark & Lunn Investment Management Ltd. Invests $652,000 in Elanco Animal Health Incorporated (NYSE:ELAN)

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 53,830 shares of the company's stock, valued at approximately $652,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC boosted its holdings in shares of Elanco Animal Health by 28.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after acquiring an additional 2,264 shares in the last quarter. DDD Partners LLC acquired a new position in Elanco Animal Health in the fourth quarter worth $5,974,000. Geode Capital Management LLC boosted its stake in Elanco Animal Health by 0.8% in the third quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company's stock worth $115,623,000 after purchasing an additional 65,303 shares in the last quarter. Atom Investors LP grew its holdings in shares of Elanco Animal Health by 310.3% during the third quarter. Atom Investors LP now owns 345,855 shares of the company's stock worth $5,081,000 after purchasing an additional 261,559 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Elanco Animal Health by 24.0% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company's stock valued at $13,135,000 after buying an additional 209,734 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Remove Ads

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock traded up $0.03 on Wednesday, reaching $10.54. 2,363,299 shares of the stock were exchanged, compared to its average volume of 4,619,554. The firm's 50 day moving average is $11.32 and its 200-day moving average is $12.51. The firm has a market cap of $5.21 billion, a PE ratio of 26.34, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a one year low of $10.03 and a one year high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the business posted $0.08 EPS. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the transaction, the director now directly owns 101,459 shares of the company's stock, valued at approximately $1,105,903.10. This represents a 10.93 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.57% of the company's stock.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of research reports. UBS Group cut their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus cut their price target on Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a report on Friday, February 21st. Leerink Partners assumed coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a "market perform" rating and a $14.00 target price for the company. Finally, Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.